Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Xofluza Filed in US to Treat Patients at High Risk of Flu-Related Complications: Shionogi
Shionogi said on March 6 that the US FDA has accepted a supplemental new drug application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of influenza in patients at a high risk of influenza-related complications aged 12 or older.The submission…
To read the full story
Related Article
- FDA OKs Xofluza for Flu Patients Carrying High Complication Risks
October 21, 2019
BUSINESS
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
- PeptiDream Poaches 3 EVPs to Bolster Global Expansion
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…